ROARABLE
FREE $100K
Today Screener Big Ideas Track Record ๐Ÿ’ฐ $100K Arena ๐ŸŽฒ Predictions ๐Ÿ›๏ธ Insiders 8 Analysts
Stock Ratings / Health Care / COCH / insiders
MYO (31) APT (61) NTRB (37) CNXU (43) โŒ˜ Pro Terminal โ†’

Envoy Medical Inc. (Class A) (COCH) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$6.63 +2.00% NASDAQ โ€ข Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.64

Envoy Medical Inc. (Class A) (COCH) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- โ€ข RED ALERT Cap $51.3M
๐Ÿ“ค Share Live RQD Speedometer Card: ๐• Post Reddit StockTwits โฌ‡ Live SVG Card
โšก INSTANT AI QUANT PREVIEW โ€ข $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on COCH Below โ€” or Connect Your Own ChatGPT / Claude
๐Ÿค– Mara Quenwick โ€ข AI Quant Lead (Click for Instant Brief) Is COCH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
โ–ผ

As of 2026-11-03, Envoy Medical Inc. (Class A) (NASDAQ: COCH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $6.63 (+2.00% 1D, market cap $51.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, COCH ranks #573 in composite RQD confidence.

โœ“ Pre-computed one-to-many AI Quant brief
๐Ÿค– Ellis Vennor โ€ข AI Peer & Flow Quant (Click for Instant Brief) How does COCH compare to MYO and APT in the Health Care sector?
โ–ผ

Within the Health Care sector (Industrial Specialties), COCH carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, MYO (Myomo Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $49.1M) and APT (Alpha Pro Tech Ltd.) posts a C- grade (61/100 RQD, P/E 16.2x, ROIC 6.7%, cap $55.1M). Among the 5-stock peer group, APT leads on earnings multiple (16.2x) while APT leads on capital efficiency (6.7% ROIC).

โœ“ Pre-computed one-to-many AI Quant brief
๐Ÿค– Gideon Ashmere โ€ข AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for COCH?
โ–ผ

Per COCH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001840877), Envoy Medical Inc. (Class A) generated $241.0K in revenue (+7.1% YoY), -$23.8M in net income, and -$18.4M in free cash flow against $8.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

โœ“ Pre-computed one-to-many AI Quant brief
๐Ÿค– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists โ€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
๐Ÿ›ก๏ธ Portfolio Crash X-Ray
EXT / AFTER-HRS: $6.64 (+0.17%)๐Ÿงฌ Disciplined Float (+0.72% YoY Shares)โš™๏ธ Cash Engine: 7/20 (D-) โ€ข 0% FCF Margin
Verify 90D Bucket Audit โ†’
๐Ÿ“Š Historical Track Record Warning: Scores below 50 (36/100 ยท D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY โ€ข 29.0% hit rate).
Audit Bucket Track Record โ†’
RQD QUANT TACHOMETERRED ALERT โ€ข D-
025507510036
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0โ€“100 RQD rubric) โ€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E ยท Rk D-
Cash (7)Whales (8)SEC (8)Macro (8)CEO (5)
Each axis scored 0โ€“20
12M PRICE TARGET CONE-10% Base Target
$10 Bull$6 Base$5 Bear
๐Ÿ“ฌ FREE COCH RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: โ€” (No Active Options Snapshot on file for COCH)Realized 20D OHLCV Swing Band: ยฑ12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
๐Ÿ” WHY COCH SCORES 36/100 (D-) โ€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
โ–ฒ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (22% of score)

20D Institutional Volume Accumulation (ยฑ12.5% realized swing band)

โ–ฒ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) โ€ข Piotroski F-Score 2/9

โ–ผ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

๐Ÿ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 โ†’ Q2 โ†’ Q3 โ†’ Current
Q1 (-3Q)
28
Grade E$6.59-3.6% Next Q
Q2 (-2Q)
31
Grade E$6.35+2.5% Next Q
Q3 (-1Q)
33
Grade E$6.51+1.8% Next Q
Current
36
Grade D-$6.63-8.3% Hist 90D ฮฑ
Trajectory: E (28) โ†’ D- (36)Full Audit โ†’
โš”๏ธ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

โš”๏ธ Adversarial Opposing Case: What Could Spark a COCH Turnaround Squeeze

Gideon Ashmere Forensic Desk โ†’

While COCH currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

๐Ÿš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

๐Ÿš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.82) and Max Pain ($6.96) forces dealer call-delta covering toward $10.02.

๐Ÿš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

๐ŸŽฒ LIVE PREDICTION MARKET ODDS TIED TO $COCHโ€ข $2.4M Crowd Pool โ€ข Kalshi / Polymarket Composite
Contract: โ€œCOCH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMAโ€
YES 36%NO 64%Trade / Inspect Odds โ†’
SEC FORM 4 ร— 13F HEDGE FUNDS ร— CONGRESSIONAL STOCK ACT

COCH Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales โ†’
โ–ฒ Disclosed Buys: 0 ($0)โ–ผ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (COCH)

No recent open-market Form 4 cluster sales or emergency dumps flagged on COCH. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP โ€ข SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring COCH)

  • โœ“Walkthrough of COCH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • โœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • โœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) โ†’$100K Arena
COCH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -4.60%โšก TESTING RESISTANCE
2026-11-03O $6.50H $6.63L $6.50C $6.63VOL 48.4K
RES: $6.96SUP: $4.64SMA50: $6.82SMA200: $6.87
$9.30$8.06$6.82$5.58$4.33RES $6.96SUP $4.64$6.632026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

COCH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

๐Ÿฆ‹ COCH Butterfly Map โ†’ + Track COCH โ†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +7.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on COCH today. View full Setup Ledger โ†’

๐Ÿฆ‹ Documented & Second-Order Butterfly Connections Open Graph โ†’

No direct multi-tier Butterfly edges indexed yet for COCH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
๐ŸŽฌ No recent verified company-specific video clip queued for COCH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk โ†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT โ€ข SEC EDGAR XBRL ร— RQD PEER BENCHMARK

๐Ÿ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (COCH)

Health Care Rank #573 of 1015 โš”๏ธ MYO vs COCH Full Matrix โ†’

1. Head-to-Head Health Care Peer Comparison (COCH vs. MYO, APT, NTRB, CNXU)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Envoy Medical Inc. (Class A) (COCH) ranks #573 by composite RQD confidence (36/100, grade D-) and #741 by equity capitalization ($51.3M). Within this direct 5-issuer industry benchmark cohort, APT leads on earnings valuation at 16.2x trailing P/E, while APT leads on capital efficiency and profitability with 6.7% ROIC and 38.1% gross margin. APT currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with COCH at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
COCH ACTIVE
Envoy Medical Inc. (Class A)
D- 36/100 โ€” -30.0% -35.0% +2.00% $51.3M Benchmark Subject
MYO
Myomo Inc.
E 31/100 โ€” 65.7% -35.0% -4.61% $49.1M /myo-vs-coch โ†’
APT
Alpha Pro Tech Ltd.
C- 61/100 16.2x 38.1% 6.7% -2.70% $55.1M /apt-vs-coch โ†’
NTRB
Nutriband Inc.
D- 37/100 โ€” 27.8% -35.0% -5.12% $76.6M /ntrb-vs-coch โ†’
CNXU
Conexeu Sciences Inc.
D- 43/100 โ€” โ€” โ€” -10.25% $77.0M /cnxu-vs-coch โ†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023โ€“FY2025)

SEC EDGAR 10-K โ€ข FILED 2025-12-31 โ€ข CIK 0001840877 โ†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Envoy Medical Inc. (Class A) (COCH) reported GAAP revenue of $241.0K (+7.1% vs. FY2024 revenue of $225.0K , and -23.7% cumulative change since FY2023) , GAAP net income of -$23.8M, operating cash flow of -$18.2M, and free cash flow of -$18.4M (+2.9% YoY). On the balance sheet, COCH closed FY2025 with $8.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $241.0K -$23.8M -$18.2M -$18.4M $8.6M โ€”
FY2024 (FY) 2024-12-31 $225.0K -$20.8M -$17.9M -$18.9M $11.5M โ€”
FY2023 (FY) 2023-12-31 $316.0K -$29.9M -$17.1M -$17.1M โ€” โ€”

3. COCH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

โœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is COCH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Envoy Medical Inc. (Class A) (NASDAQ: COCH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $6.63 (+2.00% 1D, market cap $51.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, COCH ranks #573 in composite RQD confidence.

How does COCH compare to MYO and APT in the Health Care sector?

Within the Health Care sector (Industrial Specialties), COCH carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, MYO (Myomo Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $49.1M) and APT (Alpha Pro Tech Ltd.) posts a C- grade (61/100 RQD, P/E 16.2x, ROIC 6.7%, cap $55.1M). Among the 5-stock peer group, APT leads on earnings multiple (16.2x) while APT leads on capital efficiency (6.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for COCH?

Per COCH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001840877), Envoy Medical Inc. (Class A) generated $241.0K in revenue (+7.1% YoY), -$23.8M in net income, and -$18.4M in free cash flow against $8.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is COCH trading relative to its 50-day, 200-day, and 52-week technical levels?

COCH last traded at $6.63 (+2.00% on volume of 48,375 shares), positioning the stock -2.79% below its 50-day simple moving average ($6.82) and -3.49% below its 200-day simple moving average ($6.87). Across its 52-week range of $3.63 to $9.54, COCH sits at the 50.8% percentile with a 14-day RSI of 50.9 (NEUTRAL RANGE) and an implied next-earnings move of ยฑ12.5% ($5.80 to $7.46).

Direct Sub-Reports: COCH RQD Cockpit COCH 12M Forecast COCH Earnings & Move COCH Dividends & DRIP COCH Insiders & 13F COCH Whale Options COCH Profit Sankey COCH News & Why
ROARABLE RATING BRIEF โ€ข RQD 36/100 (D-) โœ“ SEC XBRL & RQD VERIFIED

COCH โ€” Envoy Medical Inc. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Envoy Medical Inc. (Class A) (COCH) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $6.63 (+2.00% 1D, market capitalization $51.3M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of -30.0%, operating margin of -60.0%, and free cash flow yield of โ€”.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Envoy Medical Inc. (Class A) (COCH) is a NASDAQ-listed issuer in the Health Care sector, classified under the Industrial Specialties industry..1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Envoy Medical Inc. (Class A) (COCH) reported $241.0K in annual revenue (up from $225.0K in FY2024, +7.1% YoY) and -$23.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($316.0K revenue, -$29.9M net income) through FY2025, COCH scaled operating cash flow to -$18.2M and free cash flow to -$18.4M, backed by $8.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • ๐Ÿ‚ Primary Bull Case (D- โ€ข RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of โ€” and institutional whale pillar of 8/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $3.63 โ€“ $9.54 52-week range.
  • ๐Ÿป Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore โ€” The sector and industry classification (Health Care / Industrial Specialties) is the only structural context provided.

  • Key Question #1: Can COCH sustain or expand its -60.0% operating margin and -35.0% ROIC against Industrial Specialties peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $241.0K and free cash flow of -$18.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is COCH's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

COCH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Envoy Medical Inc. (Class A) (COCH) โ€ข Click "Debate This Headline" to argue it in the Roar Pit below

๐Ÿ’ฌ Jump to COCH Debate Forum (3) โ†“
๐Ÿ”ฅ THE ROAR PIT โ€ข LIVE COMMUNITY DEBATE 3 Active Posts & Replies

COCH Bull vs. Bear Conversation Board โ€” What's Your Call at $6.63?

๐Ÿ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON COCH ๐Ÿป 33% BEARISH CONVICTION
1. Pick Your Side on COCH:
๐Ÿ’ก Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER โ€ข Growth & Tech Investor ๐Ÿ‚ BULLISH ๐ŸŽฏ Target: $7.89 (+19.0%)
๐Ÿ“Œ Pinned Debate

Lake Street initiated coverage at a buy rating on the company's cochlear device.

Don't sleep on COCH's setup in Health Care. Lake Street initiated coverage at a buy rating on the company's cochlear device.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (36/100) backs up the fundamental quality.

RetailWhale_TX ๐Ÿ‚ BULL

Both sides have a point here โ€” COCH's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RI RiskArb_Desk RQD DEBATE OPENER โ€ข Hedged Event Driven ๐Ÿป BEARISH ๐ŸŽฏ Target: $5.64 (-14.9%)
Spot @ $6.63

Negative ROIC of -35% and 0% FCF yield with a Piotroski F-Score of 2 out of 9 show weak cash generation and balance-sheet signals.

Fading this rally in COCH at $6.63. Negative ROIC of -35% and 0% FCF yield with a Piotroski F-Score of 2 out of 9 show weak cash generation and balance-sheet signals.. With a beta of 1.0 and the stock sitting at $6.63 (52-wk range $3.63โ€“$9.54), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%